<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McArthur, Craig A</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The wrong paradigm may be driving drug glucose control in the face of the evidence</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">158-159</style></pages><doi><style  face="normal" font="default" size="100%">10.3399/bjgp17X690173</style></doi><volume><style face="normal" font="default" size="100%">67</style></volume><issue><style face="normal" font="default" size="100%">657</style></issue><abstract><style  face="normal" font="default" size="100%">Boussageon et al are the latest to highlight the apparent contradiction in our current thinking.1On the one hand, the epidemiological evidence shows a strong link between chronic hyperglycaemia (HbA1c) and adverse patient-important outcomes. On the other hand, the evidence from randomised controlled trial shows that lowering HbA1c by drug treatment is ineffective or harmful to patient outcomes.This contradiction is because we are using the wrong paradigm.The …</style></abstract></record></records></xml>